Hypercoagulability, endotheliopathy, and inflammation approximating 1year after recovery: Assessing the long‐term outcomes in COVID‐19 patients
Sustained hypercoagulability and endotheliopathy are present in convalescent COVID‐19 patients for up to 4 months from recovery. The hemostatic, endothelial, and inflammatory profiles of 39 recovered COVID‐19 patients were evaluated up to 16 months after recovery from COVID‐19. These values were com...
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 2022-07, Vol.97 (7), p.915-923 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 923 |
|---|---|
| container_issue | 7 |
| container_start_page | 915 |
| container_title | American journal of hematology |
| container_volume | 97 |
| creator | Fan, Bingwen Eugene Wong, Shiun Woei Christina Lai Lin Sum Lim, Gek Hsiang Leung, Bernard PuiLam Chuen Wen Tan Ramanathan, Kollengode Rinkoo Dalan Cheung, Christine Xin Rong Lim Mucheli Shravan Sadasiv David Chien Lye Young, Barnaby Edward Yap, Eng Soo Chia, Yew Woon |
| description | Sustained hypercoagulability and endotheliopathy are present in convalescent COVID‐19 patients for up to 4 months from recovery. The hemostatic, endothelial, and inflammatory profiles of 39 recovered COVID‐19 patients were evaluated up to 16 months after recovery from COVID‐19. These values were compared with a control group of healthy volunteers (n = 124). 39 patients (71.8% males, median age 43 years) were reviewed at a mean of 12.7 ± 3.6 months following recovery. One patient without cardiovascular risk factors had post COVID‐19 acute ischaemic limb. Elevated D‐dimer and Factor VIII levels above normal ranges were noted in 17.9% (7/39) and 48.7% (19/39) of patients respectively, with a higher median D‐dimer 0.34 FEU μg/mL (IQR 0.28, 0.46) (p |
| doi_str_mv | 10.1002/ajh.26575 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2675612657</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2675612657</sourcerecordid><originalsourceid>FETCH-proquest_journals_26756126573</originalsourceid><addsrcrecordid>eNqNj0FOwzAQRS1UJFJgwQ1GYkuLnRK3YYdKUVmxQWyrIZ0kjhw72A4iO46AxA05CY7UA3Q1M_99_a9h7ErwueA8vcWmnqcyW2YnLBE8l7OVzNIJS_hCirjz_IxNvW84F-JuxRP2ux06coXFqtf4rrQKww2Q2dtQk1a2w1BHAc0elCk1ti0GZQ1g1zn7pcbLVCAGQgdYBnLgqLCf5IZ7ePCevB95zAJtTfX3_RMtLdg-FLYlHzNh_fL2_BiByCGWKTLBX7DTErWny8M8Z9dPm9f1dhY7P3ryYdfY3pmIdqlcZlKMDy-Oc_0DcaBfrA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2675612657</pqid></control><display><type>article</type><title>Hypercoagulability, endotheliopathy, and inflammation approximating 1year after recovery: Assessing the long‐term outcomes in COVID‐19 patients</title><source>Wiley Online Library - AutoHoldings Journals</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Fan, Bingwen Eugene ; Wong, Shiun Woei ; Christina Lai Lin Sum ; Lim, Gek Hsiang ; Leung, Bernard PuiLam ; Chuen Wen Tan ; Ramanathan, Kollengode ; Rinkoo Dalan ; Cheung, Christine ; Xin Rong Lim ; Mucheli Shravan Sadasiv ; David Chien Lye ; Young, Barnaby Edward ; Yap, Eng Soo ; Chia, Yew Woon</creator><creatorcontrib>Fan, Bingwen Eugene ; Wong, Shiun Woei ; Christina Lai Lin Sum ; Lim, Gek Hsiang ; Leung, Bernard PuiLam ; Chuen Wen Tan ; Ramanathan, Kollengode ; Rinkoo Dalan ; Cheung, Christine ; Xin Rong Lim ; Mucheli Shravan Sadasiv ; David Chien Lye ; Young, Barnaby Edward ; Yap, Eng Soo ; Chia, Yew Woon</creatorcontrib><description>Sustained hypercoagulability and endotheliopathy are present in convalescent COVID‐19 patients for up to 4 months from recovery. The hemostatic, endothelial, and inflammatory profiles of 39 recovered COVID‐19 patients were evaluated up to 16 months after recovery from COVID‐19. These values were compared with a control group of healthy volunteers (n = 124). 39 patients (71.8% males, median age 43 years) were reviewed at a mean of 12.7 ± 3.6 months following recovery. One patient without cardiovascular risk factors had post COVID‐19 acute ischaemic limb. Elevated D‐dimer and Factor VIII levels above normal ranges were noted in 17.9% (7/39) and 48.7% (19/39) of patients respectively, with a higher median D‐dimer 0.34 FEU μg/mL (IQR 0.28, 0.46) (p < .001) and Factor VIII 150% (IQR 171, 203) (p = .004), versus controls. Thrombin generation (Thromboscreen) showed a higher median endogenous thrombin potential (ETP) of 1352 nM*min (IQR 1152, 1490) (p = .002) and a higher median peak height of 221.4 nM (IQR 170.2, 280.4) (p = 0.01) and delayed lag time 2.4 min (1.42–2.97) (p = 0.0002) versus controls. Raised vWF:Ag and ICAM‐1 levels were observed in 17.9% (7/39) and 7.7% (3/39) of patients respectively, with a higher median VWF:Ag 117% (IQR 86, 154) (p = 0.02) and ICAM‐1 54.1 ng/mL (IQR 43.8, 64.1) (p = .004) than controls. IL‐6 was noted to be raised in 35.9% (14/39) of patients, with a higher median IL‐6 of 1.5 pg/mL (IQR 0.6, 3.0) (p = 0.004) versus controls. Subgroup analysis stratifying patients by COVID‐19 severity and COVID‐19 vaccination preceding SARS‐CoV‐2 infection did not show statistically significant differences. Hypercoagulability, endothelial dysfunction, and inflammation are still detectable in some patients approximately 1 year after recovery from COVID‐19.</description><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.26575</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc</publisher><subject>Cardiovascular diseases ; Coagulation factors ; COVID-19 ; Hematology ; Inflammation ; Interleukin 6 ; Ischemia ; Risk factors ; Severe acute respiratory syndrome coronavirus 2 ; Statistical analysis ; Thrombin ; Vaccination</subject><ispartof>American journal of hematology, 2022-07, Vol.97 (7), p.915-923</ispartof><rights>2022 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Fan, Bingwen Eugene</creatorcontrib><creatorcontrib>Wong, Shiun Woei</creatorcontrib><creatorcontrib>Christina Lai Lin Sum</creatorcontrib><creatorcontrib>Lim, Gek Hsiang</creatorcontrib><creatorcontrib>Leung, Bernard PuiLam</creatorcontrib><creatorcontrib>Chuen Wen Tan</creatorcontrib><creatorcontrib>Ramanathan, Kollengode</creatorcontrib><creatorcontrib>Rinkoo Dalan</creatorcontrib><creatorcontrib>Cheung, Christine</creatorcontrib><creatorcontrib>Xin Rong Lim</creatorcontrib><creatorcontrib>Mucheli Shravan Sadasiv</creatorcontrib><creatorcontrib>David Chien Lye</creatorcontrib><creatorcontrib>Young, Barnaby Edward</creatorcontrib><creatorcontrib>Yap, Eng Soo</creatorcontrib><creatorcontrib>Chia, Yew Woon</creatorcontrib><title>Hypercoagulability, endotheliopathy, and inflammation approximating 1year after recovery: Assessing the long‐term outcomes in COVID‐19 patients</title><title>American journal of hematology</title><description>Sustained hypercoagulability and endotheliopathy are present in convalescent COVID‐19 patients for up to 4 months from recovery. The hemostatic, endothelial, and inflammatory profiles of 39 recovered COVID‐19 patients were evaluated up to 16 months after recovery from COVID‐19. These values were compared with a control group of healthy volunteers (n = 124). 39 patients (71.8% males, median age 43 years) were reviewed at a mean of 12.7 ± 3.6 months following recovery. One patient without cardiovascular risk factors had post COVID‐19 acute ischaemic limb. Elevated D‐dimer and Factor VIII levels above normal ranges were noted in 17.9% (7/39) and 48.7% (19/39) of patients respectively, with a higher median D‐dimer 0.34 FEU μg/mL (IQR 0.28, 0.46) (p < .001) and Factor VIII 150% (IQR 171, 203) (p = .004), versus controls. Thrombin generation (Thromboscreen) showed a higher median endogenous thrombin potential (ETP) of 1352 nM*min (IQR 1152, 1490) (p = .002) and a higher median peak height of 221.4 nM (IQR 170.2, 280.4) (p = 0.01) and delayed lag time 2.4 min (1.42–2.97) (p = 0.0002) versus controls. Raised vWF:Ag and ICAM‐1 levels were observed in 17.9% (7/39) and 7.7% (3/39) of patients respectively, with a higher median VWF:Ag 117% (IQR 86, 154) (p = 0.02) and ICAM‐1 54.1 ng/mL (IQR 43.8, 64.1) (p = .004) than controls. IL‐6 was noted to be raised in 35.9% (14/39) of patients, with a higher median IL‐6 of 1.5 pg/mL (IQR 0.6, 3.0) (p = 0.004) versus controls. Subgroup analysis stratifying patients by COVID‐19 severity and COVID‐19 vaccination preceding SARS‐CoV‐2 infection did not show statistically significant differences. Hypercoagulability, endothelial dysfunction, and inflammation are still detectable in some patients approximately 1 year after recovery from COVID‐19.</description><subject>Cardiovascular diseases</subject><subject>Coagulation factors</subject><subject>COVID-19</subject><subject>Hematology</subject><subject>Inflammation</subject><subject>Interleukin 6</subject><subject>Ischemia</subject><subject>Risk factors</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Statistical analysis</subject><subject>Thrombin</subject><subject>Vaccination</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqNj0FOwzAQRS1UJFJgwQ1GYkuLnRK3YYdKUVmxQWyrIZ0kjhw72A4iO46AxA05CY7UA3Q1M_99_a9h7ErwueA8vcWmnqcyW2YnLBE8l7OVzNIJS_hCirjz_IxNvW84F-JuxRP2ux06coXFqtf4rrQKww2Q2dtQk1a2w1BHAc0elCk1ti0GZQ1g1zn7pcbLVCAGQgdYBnLgqLCf5IZ7ePCevB95zAJtTfX3_RMtLdg-FLYlHzNh_fL2_BiByCGWKTLBX7DTErWny8M8Z9dPm9f1dhY7P3ryYdfY3pmIdqlcZlKMDy-Oc_0DcaBfrA</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Fan, Bingwen Eugene</creator><creator>Wong, Shiun Woei</creator><creator>Christina Lai Lin Sum</creator><creator>Lim, Gek Hsiang</creator><creator>Leung, Bernard PuiLam</creator><creator>Chuen Wen Tan</creator><creator>Ramanathan, Kollengode</creator><creator>Rinkoo Dalan</creator><creator>Cheung, Christine</creator><creator>Xin Rong Lim</creator><creator>Mucheli Shravan Sadasiv</creator><creator>David Chien Lye</creator><creator>Young, Barnaby Edward</creator><creator>Yap, Eng Soo</creator><creator>Chia, Yew Woon</creator><general>Wiley Subscription Services, Inc</general><scope>K9.</scope></search><sort><creationdate>20220701</creationdate><title>Hypercoagulability, endotheliopathy, and inflammation approximating 1year after recovery: Assessing the long‐term outcomes in COVID‐19 patients</title><author>Fan, Bingwen Eugene ; Wong, Shiun Woei ; Christina Lai Lin Sum ; Lim, Gek Hsiang ; Leung, Bernard PuiLam ; Chuen Wen Tan ; Ramanathan, Kollengode ; Rinkoo Dalan ; Cheung, Christine ; Xin Rong Lim ; Mucheli Shravan Sadasiv ; David Chien Lye ; Young, Barnaby Edward ; Yap, Eng Soo ; Chia, Yew Woon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_26756126573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cardiovascular diseases</topic><topic>Coagulation factors</topic><topic>COVID-19</topic><topic>Hematology</topic><topic>Inflammation</topic><topic>Interleukin 6</topic><topic>Ischemia</topic><topic>Risk factors</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Statistical analysis</topic><topic>Thrombin</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fan, Bingwen Eugene</creatorcontrib><creatorcontrib>Wong, Shiun Woei</creatorcontrib><creatorcontrib>Christina Lai Lin Sum</creatorcontrib><creatorcontrib>Lim, Gek Hsiang</creatorcontrib><creatorcontrib>Leung, Bernard PuiLam</creatorcontrib><creatorcontrib>Chuen Wen Tan</creatorcontrib><creatorcontrib>Ramanathan, Kollengode</creatorcontrib><creatorcontrib>Rinkoo Dalan</creatorcontrib><creatorcontrib>Cheung, Christine</creatorcontrib><creatorcontrib>Xin Rong Lim</creatorcontrib><creatorcontrib>Mucheli Shravan Sadasiv</creatorcontrib><creatorcontrib>David Chien Lye</creatorcontrib><creatorcontrib>Young, Barnaby Edward</creatorcontrib><creatorcontrib>Yap, Eng Soo</creatorcontrib><creatorcontrib>Chia, Yew Woon</creatorcontrib><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fan, Bingwen Eugene</au><au>Wong, Shiun Woei</au><au>Christina Lai Lin Sum</au><au>Lim, Gek Hsiang</au><au>Leung, Bernard PuiLam</au><au>Chuen Wen Tan</au><au>Ramanathan, Kollengode</au><au>Rinkoo Dalan</au><au>Cheung, Christine</au><au>Xin Rong Lim</au><au>Mucheli Shravan Sadasiv</au><au>David Chien Lye</au><au>Young, Barnaby Edward</au><au>Yap, Eng Soo</au><au>Chia, Yew Woon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypercoagulability, endotheliopathy, and inflammation approximating 1year after recovery: Assessing the long‐term outcomes in COVID‐19 patients</atitle><jtitle>American journal of hematology</jtitle><date>2022-07-01</date><risdate>2022</risdate><volume>97</volume><issue>7</issue><spage>915</spage><epage>923</epage><pages>915-923</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><abstract>Sustained hypercoagulability and endotheliopathy are present in convalescent COVID‐19 patients for up to 4 months from recovery. The hemostatic, endothelial, and inflammatory profiles of 39 recovered COVID‐19 patients were evaluated up to 16 months after recovery from COVID‐19. These values were compared with a control group of healthy volunteers (n = 124). 39 patients (71.8% males, median age 43 years) were reviewed at a mean of 12.7 ± 3.6 months following recovery. One patient without cardiovascular risk factors had post COVID‐19 acute ischaemic limb. Elevated D‐dimer and Factor VIII levels above normal ranges were noted in 17.9% (7/39) and 48.7% (19/39) of patients respectively, with a higher median D‐dimer 0.34 FEU μg/mL (IQR 0.28, 0.46) (p < .001) and Factor VIII 150% (IQR 171, 203) (p = .004), versus controls. Thrombin generation (Thromboscreen) showed a higher median endogenous thrombin potential (ETP) of 1352 nM*min (IQR 1152, 1490) (p = .002) and a higher median peak height of 221.4 nM (IQR 170.2, 280.4) (p = 0.01) and delayed lag time 2.4 min (1.42–2.97) (p = 0.0002) versus controls. Raised vWF:Ag and ICAM‐1 levels were observed in 17.9% (7/39) and 7.7% (3/39) of patients respectively, with a higher median VWF:Ag 117% (IQR 86, 154) (p = 0.02) and ICAM‐1 54.1 ng/mL (IQR 43.8, 64.1) (p = .004) than controls. IL‐6 was noted to be raised in 35.9% (14/39) of patients, with a higher median IL‐6 of 1.5 pg/mL (IQR 0.6, 3.0) (p = 0.004) versus controls. Subgroup analysis stratifying patients by COVID‐19 severity and COVID‐19 vaccination preceding SARS‐CoV‐2 infection did not show statistically significant differences. Hypercoagulability, endothelial dysfunction, and inflammation are still detectable in some patients approximately 1 year after recovery from COVID‐19.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/ajh.26575</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2022-07, Vol.97 (7), p.915-923 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_proquest_journals_2675612657 |
| source | Wiley Online Library - AutoHoldings Journals; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals |
| subjects | Cardiovascular diseases Coagulation factors COVID-19 Hematology Inflammation Interleukin 6 Ischemia Risk factors Severe acute respiratory syndrome coronavirus 2 Statistical analysis Thrombin Vaccination |
| title | Hypercoagulability, endotheliopathy, and inflammation approximating 1year after recovery: Assessing the long‐term outcomes in COVID‐19 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T02%3A58%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypercoagulability,%20endotheliopathy,%20and%20inflammation%20approximating%201year%20after%20recovery:%20Assessing%20the%20long%E2%80%90term%20outcomes%20in%20COVID%E2%80%9019%20patients&rft.jtitle=American%20journal%20of%20hematology&rft.au=Fan,%20Bingwen%20Eugene&rft.date=2022-07-01&rft.volume=97&rft.issue=7&rft.spage=915&rft.epage=923&rft.pages=915-923&rft.issn=0361-8609&rft.eissn=1096-8652&rft_id=info:doi/10.1002/ajh.26575&rft_dat=%3Cproquest%3E2675612657%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2675612657&rft_id=info:pmid/&rfr_iscdi=true |